Skin cancer
On this page:
Researchers at The Ottawa Hospital are leading cutting-edge studies to improve our understanding of skin cancers and develop better treatments. The major kinds of skin cancer include basal cell carcinoma, squamous cell carcinoma and melanoma.
Labs and Groups
These research teams may include multiple scientists, investigators, staff and trainees all working towards a common goal, or they can represent a single scientist and their team.
Ardolino Cancer Immunology Lab
Sabourin Lab
Ivan Litvinov
Affiliate Investigator, Cancer Research
Clinical Trials
The following list of clinical trials at The Ottawa Hospital is pulled from ClinicalTrials.gov, which is hosted by the U.S. National Library of Medicine and only available in English. If you find a clinical trial that interests you, you can bring the information to the next appointment with your care team and ask if you are eligible for the study. If so, they may be able to refer you to the study team. If you email the study team directly, we can guarantee a response. Learn more about participating in research and clinical trials.
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial (NCT05955924)
Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma View DetailsLND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (NCT06623461)
Melanoma View DetailsMelanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (NCT03860883)
Cutaneous Melanoma, Stage II View DetailsDuration of Anti-PD-1 Therapy in Metastatic Melanoma (NCT02821013)
Unresectable/Metastatic Melanoma View DetailsA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (NCT06064877)
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma View DetailsA Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05581004)
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC View DetailsA Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (NCT05538130)
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer View DetailsA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701)
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) View DetailsA Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802)
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer View DetailsA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (NCT04895709)
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms View DetailsOntario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943)
Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer View DetailsUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (NCT05111574)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma View DetailsPublications
The following research publications from The Ottawa Hospital are pulled from PubMed, with publication date of 2020 or later. Note that PubMed is hosted by the U.S. National Library of Medicine and is only available in English.
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.
2025-12-06 Go to publicationA Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
2025-11-11 Go to publicationToward standardization in esophageal cancer surgery: patterns of practice across high-volume European centers.
2025-11-01 Go to publicationThe global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
2025-10-11 Go to publicationCDKN2A deletion in p16-negative/HPV-positive head and neck squamous cell carcinoma: Highlighting the molecular basis behind the limitation of relying on p16 immunohistochemistry as a surrogate marker for HPV involvement.
2025-10-09 Go to publication